Hepatocyte mARC1 promotes fatty liver disease

Lara C. Lewis,Lingyan Chen, L.Shahul Hameed, Robert R. Kitchen,Cyrielle Maroteau,Shilpa R. Nagarajan,Jenny Norlin, Charlotte E. Daly, Iwona Szczerbinska, Sara Toftegaard Hjuler,Rahul Patel, Eilidh J. Livingstone, Tom N. Durrant, Elisabeth Wondimu,Soumik BasuRay,Anandhakumar Chandran,Wan-Hung Lee,Sile Hu, Barak Gilboa,Megan E. Grandi,Enrique M. Toledo,Abdullah H.A. Erikat,Leanne Hodson, William G. Haynes,Natalie W. Pursel, Ken Coppieters, Jan Fleckner,Joanna M.M. Howson, Birgitte Andersen,Maxwell A. Ruby

JHEP Reports（2023）

引用 7|浏览12

暂无评分

摘要

We report that genetically predicted increases in mRNA associate with poor liver health. Furthermore, knockdown of mARC1 reduces hepatic steatosis in primary human hepatocytes and a murine NASH model. Together, these findings further underscore the therapeutic potential of targeting hepatocyte for NAFLD.

查看译文

关键词

liver disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要